Adjuvant Atezolizumab Sustains Survival vs BSC in Stage IB to IIIA NSCLC

被引：0
|
作者：
Vose, Julie M. [1 ]
机构：
[1] Univ Nebraska Med Ctr, Buffett Canc Ctr, Div Hematol Oncol, Omaha, NE 68198 USA
来源：
ONCOLOGY-NEW YORK | 2024年 / 38卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：44
相关论文
共 50 条
  • [41] Preliminary Analysis of Adjuvant Chemotherapy with Atezolizumab in Stage I-III Resected NSCLC and Clearance of ctDNA
    Maniar, R.
    Shum, E.
    Mohindra, N. A.
    Owen, D. H.
    Ma, P. C.
    Haigentz, M., Jr.
    Hall, R. D.
    Rajguru, S. A.
    Grindheim, J.
    Schulze, K.
    Hanna, N. H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S117 - S118
  • [42] IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC
    Zhou, C.
    Altorki, N.
    Vallieres, E.
    Felip, E.
    Zuo, Y.
    Howland, M.
    Xia, F.
    Hoang, T.
    Sandler, A.
    Wakelee, H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] Clinical Characteristics and Survival in Stage IIIA NSCLC Patients Treated with Neoadjuvant Chemotherapy and Surgery
    Duma, Narjust
    Miranda, Claudia
    Glisch, Chad
    Harper, Harry D.
    Gutierrez, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S447 - S447
  • [44] EGFR mutation (EGFRm) prevalence and mortality in patients with stage IB-IIIA NSCLC: A cohort study in Denmark
    Jakobsen, E.
    Taylor, A.
    Ehrenstein, V.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S730 - S731
  • [45] LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET plus ) NSCLC.
    Bayt, Theresa
    Goldman, Jonathan W.
    Sands, Jacob
    Hallqvist, Andreas
    Kim, Hye Ryun
    Li, Guoping
    Wu, Lin
    Su, Weiji
    Yang, Xue-Ning
    Hochmair, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS216 - TPS216
  • [46] Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
    Brazel, Danielle
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 47 - 52
  • [47] LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET plus ) NSCLC.
    Goldman, Jonathan W.
    Sands, Jacob
    Hallqvist, Andreas
    Kim, Hye Ryun
    Li, Guoping
    Wu, Lin
    Su, Weiji
    Bayt, Theresa
    Yang, Xue-Ning
    Hochmair, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non- mall cell lung cancer (IMpower010) (vol 113, pg 4327, 2022)
    Kenmotsu, Hirotsugu
    Sugawara, Shunichi
    Watanabe, Yasutaka
    Saito, Haruhiro
    Okada, Morihito
    Yoshikawa, Toyofumi Fengshi Chen-
    Ohe, Yuichiro
    Nishio, Wataru
    Nakagawa, Shizuka
    Nagao, Haruka
    CANCER SCIENCE, 2023, 114 (05) : 2211 - 2212
  • [49] Chemotherapy and Immunotherapy in Early-Stage NSCLC: Neoadjuvant vs Adjuvant Therapy
    Wakelee, Heather
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (12) : 648 - 651
  • [50] Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
    Felip, Enriqueta
    Altorki, Nasser
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor
    Goloborodko, Oleksandr
    Luft, Alexander
    Akopov, Andrey
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Voong, David
    Wu, Fan
    Yi, Jing
    Deng, Yu
    McCleland, Mark
    Bennett, Elizabeth
    Gitlitz, Barbara
    Wakelee, Heather
    LANCET, 2021, 398 (10308): : 1344 - 1357
12345